A retrospective study assessing the response of all patients who received rituximab, polatuzamab and bendamustine (RPB) for relapsed /refractory diffuse large B cell lymphoma (DLBCL) and transformed high grade lymphoma
Latest Information Update: 05 Aug 2021
At a glance
- Drugs Bendamustine (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 05 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association